The aim of the project is the further development of an original experimental animal model for focal psychomotor epilepsy, using local injection of epileptogenic substances such as pilocarpine in discrete rat brain areas. The model will be biochemically characterized and used for the study of the mechanism and biochemical effects of existing and new anti- epileptic molecules.Thereby animal models of Parkinson's disease and epilepsy are developed. Using in vivo intracerebral microdialysis, we measure the extracellular levels of neurotransmitters in rat C.N.S. structures: dopamine, serotonin, GABA, glutamate and acetylcholine using HPLC with electrochemical or fluorimetric detection. These techniques permit the study of neurotransmitter levels after physiological or pharmacological manipulations. In a rat model for Parkinson's disease we studied the biotransformation of L-DOPA to dopamine in the striatum. In this project we will investigate further the biochemical mechanisms by which a classical drug association, L-DOPA and anticholinergics, exerts its effects. We will further investigate the biotransformation of L-DOPA at the level of the substantia nigra, the hippocampus and in structures with limited dopaminergic input such as the cerebellum and the cortex.The rat model for focal limbic seizures, further developed and characterized in this laboratory, will be used to unravel the mechanisms of action of new anti-epileptic drugs. Thereby we will focus our attention on dopamine, GABA and glutamate in the hippocampus, and the cerebellum during and after the seizures. Thereby we routinely compare biochemical data with EEG modifications.The same model will be extensively used for the evaluation of anti-epileptic effects of NMDA- and AMPA- antagonists as well as calcium entry-blockers.
|Effective start/end date||1/01/97 → 31/12/01|
Flemish discipline codes
- Basic sciences